FRANKFURT (Reuters) – Germany’s CureVac expects initial results from a late-stage trial of its COVID-19 vaccine early in the second quarter because the biotech group aims to have read-outs for specific variants.
“We need a certain number of cases for each virus variant to arrive at statistically significant results,” a spokesman said on Thursday.
The company, which on Thursday added Novartis to its line-up of vaccine contract manufacturers, has previously raised the prospect of initial trial results as early as this month.
(Reporting by Ludwig Burger; Editing by Riham Alkousaa)
